Potential risk factors for diabetic neuropathy: a case control study

被引:113
作者
Booya, F
Bandarian, F
Larijani, B [1 ]
Pajouhi, M
Nooraei, M
Lotfi, J
机构
[1] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, Iran
[2] Univ Tehran Med Sci, Dept Neurol, Shariati Hosp, Tehran, Iran
关键词
D O I
10.1186/1471-2377-5-24
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Diabetes mellitus type II afflicts at least 2 million people in Iran. Neuropathy is one of the most common complications of diabetes and lowers the patient's quality of life. Since neuropathy often leads to ulceration and amputation, we have tried to elucidate the factors that can affect its progression. Methods: In this case-control study, 110 diabetic patients were selected from the Shariati Hospital diabetes clinic. Michigan Neuropathic Diabetic Scoring (MNDS) was used to differentiate cases from controls. The diagnosis of neuropathy was confirmed by nerve conduction studies (nerve conduction velocity and electromyography). The multiple factors compared between the two groups included consumption of angiotensin converting enzyme inhibitors (ACEI), blood pressure, serum lipid level, sex, smoking, method of diabetes control and its quality. Results: Statistically significant relationships were found between neuropathy and age, gender, quality of diabetes control and duration of disease (P values in the order: 0.04, 0.04, < 0.001 and 0.005). No correlation was found with any atherosclerosis risk factor (high BP, hyperlipidemia, cigarette smoking). Conclusion: In this study, hyperglycemia was the only modifiable risk factor for diabetic neuropathy. Glycemic control reduces the incidence of neuropathy, slows its progression and improves the diabetic patient's quality of life. More attention must be paid to elderly male diabetic patients with poor diabetes control with regard to regular foot examinations and more practical education.
引用
收藏
页数:5
相关论文
共 27 条
[1]  
Ashok S, 2002, J Assoc Physicians India, V50, P546
[2]  
Barbosa AP, 2001, DIABETES METAB, V27, P496
[3]   THE PREVALENCE OF SYMPTOMATIC, DIABETIC NEUROPATHY IN AN INSULIN-TREATED POPULATION [J].
BOULTON, AJM ;
KNIGHT, G ;
DRURY, J ;
WARD, JD .
DIABETES CARE, 1985, 8 (02) :125-128
[4]  
BRAUNWALD E, 2001, HARRISON PRICNIPLES
[5]   Effects of α-lipoic acid on neurovascular function in diabetic rats:: interaction with essential fatty acids [J].
Cameron, NE ;
Cotter, MA ;
Horrobin, DH ;
Tritschler, HJ .
DIABETOLOGIA, 1998, 41 (04) :390-399
[6]  
DCCT Res Grp, 1988, DIABETES, V37, P476
[7]   THE PREVALENCE BY STAGED SEVERITY OF VARIOUS TYPES OF DIABETIC NEUROPATHY, RETINOPATHY, AND NEPHROPATHY IN A POPULATION-BASED COHORT - THE ROCHESTER DIABETIC NEUROPATHY STUDY [J].
DYCK, PJ ;
KRATZ, KM ;
KARNES, JL ;
LITCHY, WJ ;
KLEIN, R ;
PACH, JM ;
WILSON, DM ;
OBRIEN, PC ;
MELTON, LJ .
NEUROLOGY, 1993, 43 (04) :817-824
[8]  
DYCK PJ, 1999, DIABETIC NEUROPATHY
[9]   Cigarette smoking and diabetes [J].
Eliasson, B .
PROGRESS IN CARDIOVASCULAR DISEASES, 2003, 45 (05) :405-413
[10]   New insights into the pathogenesis of diabetic neuropathy [J].
Feldman, EL ;
Russell, JW ;
Sullivan, KA ;
Golovoy, D .
CURRENT OPINION IN NEUROLOGY, 1999, 12 (05) :553-563